US regulatory status: approved.
pharma · Weight Loss · Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD) · VKTX
Viking Therapeutics
Viking Therapeutics drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
San Diego, USA HQ
2012 Founded
60 Employees
Public company Type
VKTX · NYSE Ticker
Company details
- Status
- Public
- HQ
- San Diego, USA
- Founded
- 2012
- Employees
- 60
- Programs
- 6
- Drugs
- 3
- Patents
- 15
Viking Therapeutics pipeline
Portfolio lens on 3 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Viking Therapeutics drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Viking Therapeutics in public FDA and regional records.
-
Development asset linked to Viking Therapeutics in public FDA and regional records.